Solventum Corp (SOLV) stock
SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3092% above fair value
$88.81+0.19 (+0.21%)
Close on Nov 12, 2026Market cap $15.12BP/E 99.8Yield –
Solventum EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Solventum's EPS for the twelve months ending Sep 30, 2026 was $0.89, down 89.8% year over year. For fiscal 2025 it was $8.88, up 221.7% from the year before.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.88 | +221.7% |
| FY2024 | Dec 31, 2024 | $2.76 | -64.6% |
| FY2023 | Dec 31, 2023 | $7.79 | +0.1% |
| FY2022 | Dec 31, 2022 | $7.78 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.07 | -101.0% |
| Q2 FY2026 | Jun 30, 2026 | $0.53 | +3.9% |
| Q1 FY2026 | Mar 31, 2026 | $0.07 | -91.0% |
| Q4 FY2025 | Dec 31, 2025 | $0.36 | +100.0% |
| Q3 FY2025 | Sep 30, 2025 | $7.22 | +931.4% |
| Q2 FY2025 | Jun 30, 2025 | $0.51 | 0.0% |
| Q1 FY2025 | Mar 31, 2025 | $0.78 | -43.1% |
| Q4 FY2024 | Dec 31, 2024 | $0.18 | -88.5% |
| Q3 FY2024 | Sep 30, 2024 | $0.70 | -73.7% |
| Q2 FY2024 | Jun 30, 2024 | $0.51 | -72.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.37 | -19.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.57 | – |
| Q3 FY2023 | Sep 30, 2023 | $2.66 | – |
| Q2 FY2023 | Jun 30, 2023 | $1.86 | – |
| Q1 FY2023 | Mar 31, 2023 | $1.70 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?